Artivion, Inc. (NYSE: AORT), a US-based cardiac and vascular surgery company focused on aortic disease, announced on Friday that it has halted the PROACT Xa clinical trial, a prospective, randomised, trial, aimed at determining if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban rather than on warfarin.
The company has taken this decision based on the recommendation of the trial's independent Data and Safety Monitoring Board (DSMB) because of the lack of evidence supporting non-inferiority of apixaban to warfarin for valve thrombosis and thromboembolism.
The study began enrolling subjects in April 2020. The DSMB has revealed that blood clots, resulting in stroke, occurred more frequently in patients receiving apixaban and that continuing the trial was unlikely to achieve the primary endpoint while possibly exposing patients to increased risk.
Circio unveils circVec proof-of-concept
GSK releases decade-long data on Shingrix efficacy
BiVictriX receives FDA Orphan Drug Designation for AML treatment candidate
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
GSK's meningitis vaccine candidate accepted for FDA review
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
ProAxsis secures GBP1.8m investment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients